Blood platelets are produced by large bone marrow (BM) precursor cells, megakaryocytes (MKs), which extend cytoplasmic protrusions (proplatelets) into BM sinusoids. The molecular cues that control MK polarization towards sinusoids and limit transendothelial crossing to proplatelets remain unknown. Here, we show that the small GTPases Cdc42 and RhoA act as a regulatory circuit downstream of the MK-specific mechanoreceptor GPIb to coordinate polarized transendothelial platelet biogenesis. Functional deficiency of either GPIb or Cdc42 impairs transendothelial proplatelet formation. In the absence of RhoA, increased Cdc42 activity and MK hyperpolarization triggers GPIb-dependent transmigration of entire MKs into BM sinusoids. These findings position Cdc42 (go-signal) and RhoA (stop-signal) at the centre of a molecular checkpoint downstream of GPIb that controls transendothelial platelet biogenesis. Our results may open new avenues for the treatment of platelet production disorders and help to explain the thrombocytopenia in patients with Bernard-Soulier syndrome, a bleeding disorder caused by defects in GPIb-IX-V.
Blood platelets are anucleated cell fragments derived from bone marrow (BM) megakaryocytes (MKs) that are essential for blood clotting. MKs develop from haematopoietic stem cells by a complex maturation process, which includes DNA replication without cell division (endomitosis) and the formation of a demarcation membrane system (DMS), which functions as a membrane reservoir for newly formed platelets12. Mature BM MKs are giant, polylobed cells that localize close to BM sinusoids in order to extend and release long cytoplasmic protrusions called proplatelets into the sinusoidal lumen, from which platelets are shed under the influence of blood shear forces3–6. The highly controlled process of transendothelial platelet biogenesis stands in contrast to transendothelial migration of whole haematopoietic (progenitor) cells during mobilization and homing7. A current concept incorporates the idea that the chemokine stromal cell-derived factor-1 triggers migration of early MKs from the endosteal niche towards BM sinusoids8,9 and that the lipid mediator sphingosine-1-phosphate elicits directed proplatelet extension into the circulation10. However, the molecular mechanisms regulating the trafficking of MKs and haematopoietic cells within the BM and across the endothelial barrier are poorly defined.

Rho GTPases are small proteins (20–25 kDa) belonging to the superfamily of Ras-related proteins which are found in all eukaryotic cells11. They are best known for regulating cytoskeletal dynamics in virtually all cell types12. The best-characterized Rho GTPases are Cdc42, RhoA and Rac1, whose activation is for multiple comparisons) (Supplementary Fig. 1a,b). Formation of the DMS, as analysed by transmission electron microscopy (TEM), was unaltered in MKs of Gp1ba-Tg mice or wt mice after Gpibx blockade (Fig. 2b). Together, these findings revealed a critical role for the ectodomain of Gpibx in controlling MK localization at vascular sinusoids, independent of its role in DMS development and partitioning.

We next sought to get insights into the signalling that triggers Gpibx-dependent MK guidance within the BM. Using mice lacking Cdc42 in MKs and platelets (Cdc42<sup>loflo</sup> B-Fab; further referred to as Cdc42<sup>-/-</sup> (ref. 13)), we have previously shown that Cdc42 controls cytoskeletal dynamics downstream of Gpibx in platelets and that its absence in MKs causes marked macrothrombocytopenia by unknown mechanisms13. Intriguingly, significantly fewer Cdc42<sup>-/-</sup> MKs were in direct contact with BM sinusoids in line with an increased MK population in the BMHC (Fig. 2f,g) compared to wt littermate controls (52.0 ± 3.6 %; P = 0.0002; two-way ANOVA with Bonferroni correction for multiple comparisons). Importantly, Cdc42<sup>-/-</sup> MKs displayed only partially reduced membrane invaginations, indicating that the thrombocytopenia in these mice was not solely the result of a lack of intracellular membranes (Fig. 2h). Another key component of the Gpibx signalling machinery is phosphoinositide-3-kinase (PI3K) that has been shown to play an important role in thrombosis and Gpibx-induced integrin activation26,27. Of note, treatment of wt mice with the PI3K inhibitor wortmannin reduced the number of MKs in direct contact with sinusoids compared to the control (55.0 ± 5.9 %; P = 0.003; two-way ANOVA with Bonferroni correction for multiple comparisons) (Supplementary Fig. 2d,e), whereas it had no effect on DMS development or total MK numbers in the BM (Supplementary Fig. 1c), it clearly reduced the fraction of MKs with direct sinusoidal contact (39.5 ± 4.4 %; P < 0.0001; two-way ANOVA with Bonferroni correction for multiple comparisons, Fig. 2a,c). This was associated with a reduction in peripheral platelet counts and an increase in platelet size by about one third (Fig. 2d,e) as compared to wt, similar to that seen in Gpibx-Tg mice (Supplementary Fig. 1a,b). Formation of the DMS, as analysed by transmission electron microscopy (TEM), was unaltered in MKs of Gpibx-Tg mice or wt mice after Gpibx blockade (Fig. 2b). Together, these findings revealed a critical role for the ectodomain of Gpibx in controlling MK localization at vascular sinusoids, independent of its role in DMS development and partitioning.
PKGs in MKs/platelets (Supplementary Fig. 3a,b), indicating a role of the PAR complex and atypical PKCs for P13K-Cdc42 controlled MK polarization and migration/localization. Regulation of cell polarization by the PAR complex is characterized by a profound reorganization of the microtubule cytoskeleton29. Consistently, we found that microtubule disruption by nocodazole treatment prevented transmigration of RhoA-deficient MKs (Supplementary Fig. 3c,d, see below) similar to Cdc42-deficiency.

**RhoA negatively regulates GPⅠb-Cdc42 signalling in MKs.**

Rho GTPases integrate phosphoinositide signalling and cytoskeletal dynamics. This involves a cross-regulation between Cdc42 and RhoA, which tunes GTPase function in different cell types30,31. It was recently demonstrated that Cdc42 is important to polarize the MK DMS towards BM sinusoids32. Moreover, we have previously shown that mice with MK/platelet-specific RhoA-deficiency (RhoA0/0; P7a-cre, further referred to as RhoA−/−) exhibit pronounced macrothrombocytopenia (Supplementary Fig. 4a,b). This finding was striking since it was reported that RhoA negatively regulates proplatelet formation of human CD34+ derived MKs in vitro33. Supporting this result, we found that proplatelet formation of RhoA−/− fetal liver cell-derived MKs in liquid culture in vitro was comparable to the wt (Supplementary Fig. 4e (ref. 14)). Taking these observations together, we hypothesized that the apparent platelet biogenesis defect in RhoA−/− mice might be mechanistically linked to defective control of GPⅠb-Cdc42 signalling and MK localization within the BM. Intriguingly, in BM sections of RhoA−/− mice, we found a dramatic MK mislocalization with approximately 30% of the cells being present inside the BM sinusoids (27.9 ± 10%, P < 0.0001; two-way ANOVA with Bonferroni correction for multiple comparisons; Fig. 3a,b). This was striking since it was recently demonstrated that GPⅠb-negative MKs were not able to transmigrate into the vascular lumen (Fig. 3f, Supplementary Movies 3 and 4) or (iii) extended and eventually released very large proplatelet-like fragments into the circulation (Supplementary Fig. 6c, Supplementary Movie 5). Although the pulmonary microvessels represent the first capillary bed that receives circulating blood from the BM35, we did not observe increased numbers of MKs in the lungs of RhoA−/− mice (Supplementary Fig. 6d,e), suggesting that the intrasinusoidal MKs predominantly fragment in the BM vasculature or elsewhere in the circulation3. These observations collectively indicate that RhoA negatively regulates MK guidance/localization towards BM vascular sinusoids and thereby acts as a key regulator of proplatelet extension across the endothelial barrier by providing a stop-signal for MK transmigration.

To assess whether the transmigration of RhoA−/− MKs was indeed GPⅠb-dependent, we blocked the major ligand-binding site of the receptor in wt and RhoA−/− mice by injection of p0p/B-Fab. Strikingly, whereas this treatment did not affect overall MK numbers in the BM (Supplementary Fig. 7), it reduced the intrasinusoidal localization of RhoA−/− MKs by more than 70% (8.2 ± 4.4%, P < 0.001; two-way ANOVA with Bonferroni correction for multiple comparisons, Fig. 4a,d). This was associated with an increased presence of MKs in direct contact with BM sinusoids and a decreased percentage of BMHC-localized MKs compared with wt controls and vehicle-treated RhoA−/− mice, respectively (Fig. 4d). In contrast, treatment with Fab fragments of antibodies directed against the major platelet integrin 2Ⅰb3 (ON/A (ref. 36)) or GPⅤ (DOM1 (ref. 37)) did neither affect MK localization in the wt

**Figure 1 | GPⅠbα deficiency alters MK localization in the BM.** (a) Quantification of MK localization in the BM reveals less sinusoidal contact (SC) and increased localization in the BM haematopoietic compartment (BMHC) in Gp1ba−/− mice (grey) compared to the wild-type (wt, black) (n = 5); intrasinusoidal (intrasin.). (b) Representative confocal images of immunostained BM of wt and Gp1ba−/− mice. Scale bars, 50 μm. MKs, platelets and platelets are shown by CD41 staining in green. Endoglin staining (red) labels vessels. DAPI, blue. Arrowhead indicates MKs in the BM haematopoietic compartment.
(Supplementary Fig. 7b,c), nor was it able to revert the transendothelial migration of RhoA−/− MKs, demonstrating a specific role for GPIb in these processes. We also generated RhoA−/−/Gp1ba-Tg mice, in which we found similar results as compared to p0p/B-Fab treatment (9.5 ± 4.5% MKs intra-sinusoidal, Fig. 4b,d). Interestingly, inhibition of PI3K by...
wortmannin treatment likewise significantly reduced the number of intrasinusoidal MKs in RhoA\(^{-/-}\) mice (12.3 ± 5.2%, \(P < 0.0001\); two-way ANOVA with Bonferroni correction for multiple comparisons), but did not increase the number of MKs with direct sinusoidal contact (Supplementary Fig. 2d,e). Total MK numbers in the BM were unaltered in wortmannin-treated compared to vehicle-treated RhoA\(^{-/-}\) mice (Supplementary Fig. 2f) and also their DMS appeared largely unaltered (Supplementary Fig. 2c).

Together, these data indicate that RhoA may act as a negative regulator of GPIb\(\alpha\)-Cdc42-driven MK guidance towards BM sinusoids and transendothelial migration. To further test this hypothesis, we generated MK/platelet-specific RhoA/Cdc42-double-deficient mice (RhoA/Cdc42\(^{-/-}\) Pf4-cre, further referred to as RhoA/Cdc42\(^{-/-}\); Supplementary Figs 8a and 11a–c). Strikingly, RhoA/Cdc42\(^{-/-}\) MKs massively accumulated around vascular sinusoids (82.9 ± 5.9%, \(P = 0.0002\); two-way ANOVA with Bonferroni correction for multiple comparisons, Supplementary Movie 6), but failed to transmigrate into the lumen (3.9 ± 1.8% MKs intrasinusoidal, Fig. 4c,e) or to efficiently form transendothelial proplatelets \(in\) \(vivo\) (Fig. 4f,g, Supplementary Movie 6). Consequently, these animals were severely thrombocytopenic (Supplementary Fig. 8b,c). Of note, intrasinusoidal localization of RhoA\(^{-/-}\) MKs was not altered by the concomitant lack of Rac1 (RhoA/Rac1\(^{-/-}\)) (Supplementary Fig. 9a–e), thus indicating a specific RhoA-Cdc42 crosstalk downstream of GPIb\(\alpha\) in this process.

RhoA controls MK polarization by limiting Cdc42 activity. We next investigated whether a possible crosstalk between Cdc42 and RhoA regulates MK polarization. Importantly, mature
Cdc42^{−/−} and Gp1ba-Tg BM MKs displayed defective DMS polarization after 4 days of liquid culture in vitro (Fig. 5a–c), whereas increased polarization of not fully mature DMS was observed in RhoA^{−/−} MKs (Fig. 5d,g). Strikingly, in vitro treatment with p0p/B-Fab (anti-GPIb) markedly reduced DMS polarization in cultures of both wt and RhoA^{−/−} BM MKs (Fig. 5e,g), suggesting that the regulatory role of GPIb in this process depends on intracytoplasmic GPIb-IX-V signalling and may operate in the absence of an ectopic ligand.

To decipher the underlying mechanism, we took advantage of lentiviral FRET biosensors derived from the Raichu probe to monitor Cdc42 activity in the polarized DMS32. WT MKs showed a polarized Cdc42 activity at the DMS/F-actin complex, which was reduced by 68% in Gp1ba-Tg MKs (Fig. 6a,b,d), demonstrating the importance of controlled Cdc42 activation by GPIb for correct DMS polarization. Strikingly, polarized Cdc42 activity showed a 2.4-fold increase in the absence of RhoA (Fig. 6c,d), indicating that RhoA controls DMS and subsequently MK polarization by limiting Cdc42 activity. In order to determine how the nucleotide state of Cdc42 and RhoA influences this regulation, we utilized single amino acid mutants Cdc42/F28L and RhoA/F30L known to induce a constitutive exchange of GDP for GTP, thus resulting in hyperactive GTPases38. To restrict the expression of these mutants to the megakaryocytic lineage, we expression of these mutants to the megakaryocytic lineage, we generated BM chimeric mice by transplantation of HSCs after lentiviral gene transfer, in which proteins were expressed under transcriptional control of the MK/platelet-specific human GP6 promoter (Fig. 7a,b)39. Of note, control mice transplanted with GFP-expressing HSCs showed reduced sinusoidal MK localization compared with non-irradiated mice (44.3 ± 2.94%, Fig. 7c,d,f), indicating that irradiation influences MK localization. Compared to GFP-positive control cells, vessel association of Cdc42/F28L expressing MKs (GFP^{+}/GPIX^{+}) was increased (57.0 ± 9.0%, Fig. 7c,d,f) and approx. 4% of mutant MKs were...
located inside the BM sinusoids, whereas none were found in this compartment in control mice (Fig. 7c,d,f). In contrast, RhoA/F30L expression resulted in a further reduction of MKs in direct contact with BM sinusoids (30.4 ± 6.4%, Fig. 7c,e,f) confirming the opposing functions of active Cdc42 (go-signal) and RhoA (stop-signal) in controlling MK localization and transendothelial proplatelet formation (Fig. 8).

**Discussion**

MKs are unique among haematopoietic progenitor cells in that they normally do not cross the endothelial lining of BM sinusoids, but extend and release portions of their cytoplasm into the blood stream by so far unknown mechanisms. We now provide compelling evidence that this key step of unidirectional transendothelial proplatelet formation is tightly controlled.
RhoA controls GPIbα-induced MK polarization by limiting Cdc42 activity. (a–c) Cultured mouse MKs were transduced with Raichu-Cdc42 lentiviral vector. F-actin was stained with phalloidin (blue); GPIbα, red; DAPI, cyan. Cdc42 activation was visualized by colour-coded FRET. High ratio values (red) correlate with higher Cdc42 activity. Active Cdc42 localizes with the polarized F-actin/DMS complex and its activity is decreased in Gp1ba−/−:Tg (Gp1ba-Tg) and increased in RhoA−/− MKs. Scale bar: 10 µm. (d) Quantification reveals decreased Cdc42 activity in Gp1ba−/−:Tg (light grey) and increased activity in RhoA−/− (dark grey) polarized MKs compared to the wt (black) (n = 4 biological replicates). Bar graphs represent mean ± s.d. Two-way ANOVA with Bonferroni correction for multiple comparisons; *P < 0.05; **P < 0.001.

Within MKs by a crosstalk of Cdc42 and RhoA and requires a functional GPIbα ectodomain to occur efficiently (Fig. 8). Our data reveal a central antagonistic role of Cdc42 and RhoA in MK polarization and suggest that absence of RhoA supports locally increased Cdc42 activity and thereby directs the sites of cell protrusion. Our findings also highlight a critical function of the GPIbα ectodomain for efficient MK polarization, Cdc42 activation and thus sinusoidal localization and transendothelial proplatelet formation of mature MKs. Thus, these data indicate that MK mislocalization within the BM contributes to the low platelet counts in BSS patients and may mechanistically explain the defective transendothelial (pro-)platelet formation by impaired DMS polarization and Cdc42 activation.

Of note, vWF-deficient humans and mice display normal platelet counts40, and MK localization in the BM was not altered in Vwf−/− mice (Supplementary Fig. 10a,b), which excludes a major role of this ligand in GPIbα-dependent MK polarization.

Besides the vWF binding site, the p0p/B antibody Fab fragment also completely blocks thrombin binding to mouse GPIbα (Supplementary Fig. 10c), raising the possibility that this process might play a role in MK localization/polarization. However, MK localization in the BM of mice expressing human GPIbα with a mutation (D277N) that abolishes χ-thrombin binding was similar to that of mice expressing wt hGPIbα (Supplementary Fig. 10d,e), arguing against a role of thrombin in this process. Intriguingly, however, in vitro treatment of cultured MKs with p0p/B-Fab was sufficient to almost completely revert the DMS hyperpolarization observed in RhoA-deficient MKs. Thus, our findings do not indicate that GPIbα requires binding of an ectopic ligand to control MK localization and polarization in the BM. Rather, our results support the hypothesis that GPIbα-mediated regulation of MK polarization might be a cell intrinsic process, which can be modulated by altering GPIbα signalling through changing the conformation and/or membrane localization/ clustering of the receptor in response to p0p/B-Fab binding. In line with this, enhanced endogenous binding of mutant vWF to GPIbα in patients with vWF disease-type 2B results in giant platelets and thrombocytopenia and was reported to be associated with dysregulation of the LIM kinase/cofilin pathway in MKs, together with upregulated RhoA signalling42. Thus, altered GPIb-IX-V-mediated intracellular signalling can lead to abnormal cytoskeletal signalling and severely abnormal MK function.

Taken all observations together, our data support a model in which GPIbα controls MK localization and transendothelial MK migration through intracellular signals, namely through the regulation of cell polarization via the Rho GTPases RhoA and Cdc42. While this process presumably involves MK PI3K function, we cannot rule out that treatment with the PI3K inhibitor wortmannin also exerts effects on vascular cells. Thus, deciphering the exact role of PI3K and/or PIs in MK localization requires further investigation. On the other hand, it is well known that Cdc42 and PI3K play a central role in establishing morphological and molecular cell polarity in eukaryotic cells28,29.

In neurons, establishment of cell polarity during axon specification requires PI3K-dependent crosstalk of GTPases with aPKC isoforms which form part of the PAR complex28. Consistently, Cdc42-mediated cell polarity in migrating astrocytes occurs through activation of the aPKC isoform PKCζ28,43. Thus, our observation of reduced sinusoidal localization of MKs in wortmannin-treated mice and mice deficient in the PI3K function. We cannot rule out that treatment with the PI3K inhibitor wortmannin also exerts effects on vascular cells. Thus, deciphering the exact role of PI3K and/or PIs in MK localization requires further investigation. On the other hand, it is well known that Cdc42 and PI3K play a central role in establishing morphological and molecular cell polarity in eukaryotic cells28,29.

In neurons, establishment of cell polarity during axon specification requires PI3K-dependent crosstalk of GTPases with aPKC isoforms which form part of the PAR complex28. Consistently, Cdc42-mediated cell polarity in migrating astrocytes occurs through activation of the aPKC isoform PKCζ28,43. Thus, our observation of reduced sinusoidal localization of MKs in wortmannin-treated mice and mice deficient in the PI3K function. We cannot rule out that treatment with the PI3K inhibitor wortmannin also exerts effects on vascular cells. Thus, deciphering the exact role of PI3K and/or PIs in MK localization requires further investigation. On the other hand, it is well known that Cdc42 and PI3K play a central role in establishing morphological and molecular cell polarity in eukaryotic cells28,29.
GPIb-IX-V complex and multiple cytoskeletal proteins including Filamin A, non-muscle myosin IIa (NMM-IIa), β-tubulin, α-actinin and Diaphanous Related Formin 1 (DIAPH1) that control the late stages of MK maturation with defects in individual proteins all giving rise to macrothrombocytopenia40,44. Interaction of the cytoplasmic domain of GPIbα with Filamin A provides a major link between the receptor and the MK cytoskeleton and coordinated expression of GPIbα and Filamin A is required for proper localization of either protein45. Deficiency of Filamin A in MKs was shown to affect DMS formation46 and results in premature release of large, fragile platelets in humans and mice47,48. Together with the observation that polarity in osteoclasts depends on a network involving both Filamin A and Cdc42 (ref. 49) this points to a critical role of Filamin A for the transmission of signalling between GPIbα and Cdc42.

**Figure 7 | Activation states of RhoA and Cdc42 have opposing functions in MK localization.** (a) Third-generation self-inactivating lentiviral vectors were generated, expressing Cdc42F28L and RhoAF30L, respectively, together with GFP through an IRES, or just GFP under control of the MK-specific human GP6 promoter in the internal position. (b) Work-flow. Lineage marker-negative (Lin–) BM cells were isolated, pre-stimulated for 24 h and transduced twice. Cells were then transplanted into conditioned recipient mice. (c–e) Representative confocal images of immunostained BM of wt mice after BM transplantation of wt HSC transduced with GFP (c), constitutive active Cdc42 (F28L) (d) or constitutive active RhoA (F30L) (e). Scale bars, 50 μm. MKs, proplatelets and platelets are shown by GPIX staining in cyan colour. Endoglin staining (red) labels vessels. DAPI, blue. Arrowhead indicates MKs in BMHC, asterisk indicates intrasinusoidal MKs. (f) Quantification of MK localization in the BM (n = 4). Quantification of MK localization in non-irradiated wt mice (white) are shown to demonstrate altered localization after irradiation and transplantation of wt cells. Bar graphs represent mean ± s.d. Two-way ANOVA with Bonferroni correction for multiple comparisons. *P < 0.05, compared to wt + GFP; #P < 0.05, compared to wt not transplanted.
Our data from RhoA-deficient mice clearly exclude that size restrictions limit MK transmigration through BM sinusoids and emphasizes RhoA as a critical regulator of proplatelet extension across the endothelial barrier by providing a 'stop' signal for MK polarization and thus transmigration (Fig. 8). In line with this, it has been described that excessive RhoA activation in BM-derived macrophages leads to decreased polarization, motility and cell spreading. Of note, RhoA-dependent activation of Rho kinase (ROCK) and NMM-IIa was shown to negatively regulate proplatelet formation in MKs derived from CD34+ cells in vitro. Mutations in the gene encoding NMM-IIa, MYH9, affect platelet biogenesis in patients with MYH9-related disorders. Interestingly, MKs from mice with MK-restricted NMM-IIa deficiency (Myh9−/−) exhibit increased proplatelet formation in vitro and a significant number of MK nuclei was observed in lungs of Myh9−/− animals compared to the wild-type. However, given the multiple intrinsic defects present in Myh9−/− MKs, further studies using different experimental approaches will be required to decipher the role of NMM-IIa in RhoA-induced MK polarization and platelet biogenesis.

In summary, the herein described Cdc42/RhoA regulatory circuit downstream of GPib ensures a tight control of transendothelial platelet biogenesis in the BM and opens new avenues to treat both inherited and acquired forms of thrombocytopenia that are major causes of bleeding in man, and additionally to modulate in vitro production of platelets in the field of transfusion medicine.

**Methods**

**Mice.** All animal experiments, except studies involving BM transplantation, were carried out in the Institute of Experimental Biomedicine (Würzburg) and approved by the district government of Lower Frankonia (Bezirksregierung Unterfranken). BM transplantation experiments were carried out at the Paul-Ehrlich-Institute (Langen) and approved by the local ethics committee of the Lower Saxony State Office (according to §15 German animal protection law). Cdc42−/− mice (C57Bl/6 background), Gp1ba−/− mice (C57Bl/6 background), Rac1−/− mice (C57Bl/6 background), and mice (both mixed C57Bl/6 and SV129 background), carrying the Cre-recombinase under the platelet factor 4 (PF4) promoter, have been described. MK/platelet-specific conditional RhoA- and Cdc42-deficient mice (both mixed C57Bl/6 and SV129 background), carrying the Cre-recombinase under the platelet factor 4 (PF4) promoter, have been described. RhoA−/− mice were intercrossed with Gp1ba−/− mice to generate RhoA−/−/Gp1ba−/− mice, with Cdc42−/− mice to generate RhoA/Cdc42−/− mice, and with Rac1−/− mice (mixed C57Bl/6 and SV129 background) to generate RhoA/Rac1−/− mice. Myh9−/− mice kindly provided by Dr Michael Leitges (VitaTherapy) were kindly provided by Dr Cecile Denis. Mice used in experiments were 8 to 16 weeks old and sex-matched (both sexes used), if not stated otherwise.

**Antibodies and reagents.** Anaesthetic drugs (medetomidine (Pfizer), midazolam (Roche) and fentanyl (Janssen-Cilag)) were used according to the regulations of the district government of Lower Frankonia (Bezirksregierung Unterfranken). Mice were bled into high-molecular-weight heparin (Ratiopharm). Mice were treated with the selective PI3K inhibitor wortmannin (Sigma-Aldrich; 1 μg·kg−1 body weight; days 1 and 3), the microtubule polymerization inhibitor nocodazole (Sigma-Aldrich; 10 μg·ml−1 body weight; days 1–3), or with monovalent Fab fragments of antibodies directed against the major ligand-binding domain of GPibα (pol/β-Fab (ref. 25); 100 μg per mouse, days 1 and 3), or with monovalent Fab fragments directed against the major ligand-binding domain of GPibα (pol/β-Fab (ref. 25); 100 μg per mouse, days 1 and 3), or with monovalent Fab fragments of antibodies directed against the major ligand-binding domain of GPibα (pol/β-Fab (ref. 25); 100 μg per mouse, days 1–3). Fab or F(ab)2 fragments was tested by SDS-PAGE. For control experiments, purified rat IgG2a (Serotec) and nonimmune control rat IgG were used. Purity of Fab or F(ab)2 fragments was tested by SDS-PAGE. For control experiments, purified rat IgG2a (Serotec) and nonimmune control rat IgG Fab were used.

**Immunofluorescence staining on whole femora cryosections.** Femora were isolated, fixed with 4% PFA (AppliChem) and 5 mM sucrose (Sigma-Aldrich), transferred into 10% sucrose in PBS and dehydrated using a graded sucrose series. Subsequently, the samples were embedded in Cryo- Gel (Leica Biosystems) and shock frozen in liquid nitrogen. Frozen sections were stored at −80 °C. Seven-micrometer-thick cryosections were generated using the cryo-jane tape transfer system (Leica Biosystems) and probed with Alexa488-conjugated anti-GPibα antibody, to specifically label platelets and MKs, and Alexa647-conjugated anti-CD105 antibodies (3.33 mg ml−1, 22402 (MF718), BioLegend) to stain the endothelium. Nuclei were stained using DAPI (4,6-diamido-2-phenylindole; 1 μg ml−1; D1306, Invitrogen). Samples were visualized with a Leica TCS SP5 confocal microscope (Leica Microsystems).

**TEM of bone marrow megakaryocytes.** For TEM of MKs, BM was flushed from 12- to 16-week-old mice using Karnovsky fixative (2% PFA, 2.5% glutaraldehyde

---

**Figure 8** | Model of the Cdc42/RhoA regulatory circuit controlling GPibα-dependent platelet biogenesis. (a) Wt BM MKs polarize their DMS as prerequisite for directed proplatelet release into sinusoidal vessels. This polarization is driven by locally active Cdc42. (b) Perturbed intracellular GPibα-signalling reduces local Cdc42 activity and results in defective DMS polarization, reduced MK localization at BM sinusoids and decreased transendothelial proplatelet formation. (c) In the absence of RhoA, Cdc42 activity is locally increased resulting in hyperpolarized MKs entirely transmigrating through the endothelial barrier into sinusoidal vessels.
in 0.1 M caccodylate buffer) and incubated overnight at 4 °C. Subsequently, fatty components of the samples were fixed with 2% osmium tetroxide in 50 mM sodium cacodylate (pH 7.2), stained with 0.5% aqueous uranyl acetate, dehydrated with a graded ethanol series and embedded in Epon 812. Ultra-thin sections were stained with 2% uranyl acetate (in 100% ethanol) followed by lead citrate. Images were taken on a Zeiss EM900 TEM (Zeiss). Imagej software (Wayne Rasband, NIH, USA: http://rsb.info.nih.gov/ij) was used to quantify DMS.

Two-photon intravital microscopy of the BM. Mice were anesthetized by intraperitoneal injection of medetomidine 0.3 μg g−1, midazolam 5 μg g−1 and fentanyl 0.05 μg g−1 body weight. A 1 cm incision was made along the midline to expose the femurotapetal skull, while carefully avoiding damage to the bone tissue. The mouse was placed on a customized metal stage equipped with a stereotactic holder to immobilize its head. BM vasculature was visualized by injection of tetramethylrhodamine dextran (8 kDa; 1 μg g−1 body weight, 2 MDA, Thermo Scientific). Platelets and MKs were antibody stained with anti-GPIX-AlexaFluor 488 (i.e. injection of 0.6 μg g−1 body weight). Images were acquired with a fluorescence microscope equipped with a ×20 water objective with a numerical aperture of 0.95 and a TrinM Scope II multimorphon system (LaVision BioTec), controlled by ImSpector Pro-V380 software (LaVision BioTec). Emission was detected with HQ535/50-nm and ET605/70-nm filters. A tunable broad-band Ti:Sa laser (Chameleon, Coherent) was used at 760 nm to capture Alexa Fluor 488 and rhodamine dextran fluorescence. Imagej software (NIH) was used to generate movies.

Flow cytometry. Diluted blood (1:20) was incubated for 15 min at room temperature (RT) with fluorescence-activated cell sorter (FACS) buffers (Biologend) directed against platelet surface GPIbα. Platelet count and size (forward scatter) were assessed using a FACSCalibur (BD Biosciences) flow cytometer.

Immunodotting. Denaturated platelet lysates were separated by SDS–PAGE and blotted onto polyvinylidene difluoride membranes. Membranes were incubated with anti-RhoA antibody (0.5 μg ml−1, Cytoskeleton Inc.), anti-Cdc42 antibody (0.5 μg ml−1, BD Biosciences) antibodies followed by incubation with appropriate horseradish peroxidase-conjugated secondary antibodies (1 h, room temperature) and enhanced chemiluminescence solution (Millipore). Images were recorded using a Multitimage II FC Light Cabin (Alpha Innotech Corporation) device. As loading control, integrin β3 (GPIIIa) levels were determined.

Histology. Three-micrometer-thick sections of formalin-fixed paraffin-embedded spleens and lungs were prepared, deparaffinized and stained with haematoxylin and eosin (MHS32 and 318906, Sigma-Aldrich). MKs were stained with L-glutamine, 100 IU ml−1, penicillin, 50 μg ml−1 streptomycin and 20 ng ml−1 murine stem cell factor, 15 IU ml−1 heparin and 50 ng ml−1 of mTPo at 37 °C under 5% CO2 for 3 days. Where indicated, MK cultures were supplemented daily with 50 μg ml−1 of p0p/B-Fab fragment. Mature MKs were enriched by a one-step BsA gradient.

Analysis of MK polarization. For immunofluorescence, MKs in suspension were fixed and permeabilized in one step for 30 min in PBS with 3.7% formaldehyde and 0.05% Triton X-100. Samples were saturated in 1% fatty acid free BSA in PBS. Incubation with antibodies, fluorescent secondary antibodies, AlexaFluor-labelled phalloidin or DAPI was performed for 1 h at RT. Cells were then washed in μ-slide ibiTreat chambers (Ibidi) in PBS. Confocal images were captured with an LSM780 operated with Zen software using a ×63, 1.4 NA Plan Apochromatic objective lens (Carl Zeiss). Profiling of fluorescence intensity was done with ImageJ (NIH). For 3D-analysis, z-stacks were taken and processed with the Imaris 6.2 software (Bitplane AG).

FRET-based measurement of Cdc42 activity. The Raichu-Cdc42 encoding sequence was amplified by PCR using Raichu-1054X plasmid as a template and cloned in frame into the pTRP-RES lentiviral vector plasmid using BamHI and Nhel restriction sites (underlined)2. The primers were 5′-CCGGGATCCCTTGGGAAAGAATTCCGGATCAG-3′ (forward) and 5′-CTAGCTAGCGGAGGAGGAAGAAGATCGGTTGACAC-3′ (reverse). UT711oc1 cells were transduced by incubation with lentiviral particles at a multiplicity of infection (MOI) of 1 for 2 days. Transduction efficiency was checked by fluorescence and reached about 100% of the population. Transduction of primary MKs was performed on Lin− population

at an MOI of 5 for 1 day, then 50 ng ml−1 mTPO were added for 3 additional days. FRET efficiency was represented as the colour-coded ratio image of YFP:CFP after background subtraction using ImageJ (Universal Imaging). Acquisitions were performed with a LSM780 confocal microscope piloted by the Zen software, using a ×63, 1.4 NA Plan Apochromatic lens (Carl Zeiss).

Lentiviral gene transfer of Rho GTPase mutants. The CDNAs of Cdc42F28L and RhoA3F0L were inserted into lentiviral vectors upstream of an IRES co-expressing eGFP as reporter (lentiviral vector RLL-PPT.SF.eGFP.pre kindly provided by A. Schambach, Hannover Medical School)24. Expression was controlled by the MK-specific human Gp6 promoter (hGp6, −697 to −29 (ref. 39)). Lentiviral particles were produced by transient transfection in 293T cells. The day before transfection, 5 × 105 293T cells were seeded in 10 cm plates in DMEM medium containing 10% fetal calf serum, 1% glutamine, 1% penicillin/streptomycin, 20 mM HEPES. The next day, 293T cells were transfected by calcium-phosphate transfection method with 10 μg of vector plasmid, 10 μg gag/pol plasmid (pCD3.G4-PX.CM) and 1.5 μg plasmid encoding the VSV-G envelope (pMD.G plasmid), 5 μg Rev encoding plasmid in DMEM medium supplemented with 25 μM of chloroquine. Lentiviral supernatants were collected after 36 and 48 h post transfection, and concentrated by ultra-speed centrifugation at 80,000 g × 2 h. Concentrated viral particles were resuspended in StemSpan medium (Stem Cell Technologies, Köln, Germany) and stored at −80 °C. Prior to viral transduction, Lin− BM cells were pre-stimulated for 24–48 h in StemSpan containing 10 ng ml−1 murine stem cell factor, 20 ng ml−1 murine TPO, 10 ng ml−1 recombinant human FGF-1, 20 ng ml−1 murine IgGF2, 1% penicillin/streptomycin, 2 mM glutamine. 5 × 105 Lin− cells were transduced twice on two following days with lentiviral vectors on Retronectin (Takara-Clontech, 10 μg cm−2) coated wells (24-well or 12-well plates, dependent on the number of cells for transduction, with a defined MOI).

BM transplantation. 8–12-week-old female C57Bl/6 mice were preconditioned with 10 Gy irradiation and transplanted with 5 × 10^6 cells. Cell infusion was performed via tail vein injection in a final volume of 150 μl. All mice were kept in the specified pathogen-free animal facilities of the Paul-Ehrlich-Institute, Langen, Germany.

Statistical analysis. When comparing two experimental groups, data distribution was analysed using the Shapiro–Wilks test. Where indicated, statistical significance between two experimental groups was analysed using an unpaired two-tailed Student’s t-test. Otherwise, data were analysed using two-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons (Prism 7; GraphPad Software). P-values <0.05 were considered as statistically significant. *P<0.05; **P<0.01; ***P<0.001 or as otherwise stated. Data are presented as mean ± s.d.

Data availability. All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

References
1. Machlus, K. R. & Italiano, Jr J. E. The incredible journey: from megakaryocyte development to platelet formation. J. cell biol. 201, 785–796 (2013).
2. Schulze, H. et al. Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. Blood 107, 3868–3875 (2006).
3. Behneke, O. & Forer, A. From megakaryocytes to platelets: platelet morphogenesis takes place in the bloodstream. Eur. j. haematol. Suppl. 61, 3–23 (1998).
4. Junt, T. et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 317, 1767–1770 (2007).
5. Patel, S. R., Hartwig, J. H. & Gisselsson, D., Jr J. E. The biogenesis of platelets from megakaryocytes happens. J. clin. invest. 115, 3348–3354 (2005).
6. Nishimura, S. et al. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J. cell biol. 209, 453–466 (2015).
7. Möhle, R., Bautz, F., Denzlanger, C. & Kanz, L. Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factors. Ann. NY Acad. Sci. 938, 26–34 discussion 34 (2001).
8. Aveicilla, S. T. et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat. med. 10, 64–71 (2004).
9. Pitchford, S. C., Lodie, T. & Rankin, S. M. VEGF1 stimulates a CXCR4-dependent translocation of megakaryocytes to the vascular niche, enhancing platelet production in mice. Blood 120, 2787–2795 (2012).
10. Zhang, L. et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J. exp. med. 209, 2165–2181 (2012).
11. Andre, P. et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 96, 3322–3328 (2000).
12. Vasudevan, S. et al. Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ibα/β. J. biol. chem. 275, 12763–12768 (2000).
13. Pleines, I. et al. Multiple alterations of platelet functions dominated by increased secretion in mice lacking Cdc42 in platelets. Blood 115, 3564–3573 (2010).
14. Pleines, I. et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood 119, 1054–1063 (2012).
15. Bernard, J. & Soulier, J. P. Sur une nouvelle variété de dystrophie thrombocytaire hémorragique congénitale. La semaine des hopitaux: organes fonde par l’Association d’enseignement médical des hopitaux de Paris 24, 3217–3223 (1948).
16. Lopez, J. A., Andrews, R. K., Ashfar-Kharghan, V. & Berndt, M. C. Bernard-Soulier syndrome. Blood 91, 4397–4418 (1998).
17. B. N. conceived the study, designed research, analysed data and wrote the manuscript. J. M. M. v. E. and A. A. B. performed experiments. O. A., M. G. and F. G. and N. H. performed experiments and analysed the data. J. M. M. v. E. and D. S. and K. H. G. provided financial support. This work was supported by the Deutsche Forschungsgemeinschaft (NI 556/9-1 to B.N., SFB688 to D.S. and K.G.H., and PL 707/2-1 to I.P.) and the Rudolf Virchow Center. S.S., J.M.M.v.E., D.C. and A.A.B. performed experiments. O.A., M.G. and F.G. and N.H. performed experiments and analysed the data.

Acknowledgements

We thank Jonas Müller, Stefanie Hartmann, Sylvia Hengst and Franziska Schenk for excellent technical assistance and Inke Meyer for initial support during multi-photon microscopy. We are also thankful to the microscopy platform of the Bioimaging Centre (Rudolf Virchow Centre) and of the INSERM UMR1048, especially E. Vega, for providing technical infrastructure and support. This work was supported by the Bundesministerium für Bildung und Forschung (BMBF), and the German Research Foundation (DFG). We are grateful to the Rudolf Virchow Center for providing technical infrastructure and support. This work was supported by the Deutsche Forschungsgemeinschaft (NI 556/9-1 to B.N., SFB688 to D.S. and K.G.H., and PL 707/2-1 to I.P.) and the Rudolf Virchow Centre. The Cdc42 guanine nucleotide exchange factor FGD6 coordinates cell polarity and endosomal membrane recycling in osteoclasts. J. biol. chem. 289, 18347–18359 (2014).

Plexy. F. J. et al. BCL6 suppresses RhoA activity to alter macrophage morphology and motility. J. cell. sci. 118, 1873–1883 (2005).
18. Nurden, A. T. Qualitative disorders of platelets and megakaryocytes. J. thromb. haemost. 3, 1773–1782 (2005).
19. Eckly, A. et al. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MTH9 inactivation. Blood 113, 3182–3189 (2009).
20. Leon, C. et al. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. Blood 119, 3333–3341 (2012).
21. Seidl, S. et al. Phenotypical analysis of atypical PKCs in vivo function display a compensatory system at mouse embryonic day 7.5. PLoS ONE 8, e62756 (2013).
22. Tie, R., Schomer, T., Hao-Shen, H. & Skoda, R. C. P6-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood 109, 1503–1506 (2007).
23. Denis, C. et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl Acad. Sci. USA 95, 9524–9529 (1998).
24. Dwut, S. et al. Growth factor receptor-bond protein 2 contributes to (hem)immunoreceptor tyrosine-based activation motif-mediated signaling in platelets. Circ. res. 114, 444–453 (2014).
25. Schambach, A. et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of the O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol. ther. 13, 391–400 (2006).
26. Holms, M. L., Bartle, N., Eibacher, M. & Chong, B. H. Cloning and analysis of the thrombopoietin-induced megakaryocyte-specific glycoprotein VI promoter and its regulation by GATA-1, Fli-1, and Sp1. J. biol. chem. 277, 48333–48341 (2002).

Authors contributions

S.D. designed research, performed experiments, analysed data and wrote the manuscript. M.P., A.A., T.H., K.A., F.G. and N.H. performed experiments and analysed the data. D.S., S.S., D.C., P.N., U.M., I.P., and F.G.-I. performed experiments, analysed data and wrote the manuscript. J.M.M.v.E. and A.A.B. performed experiments. O.A., M.G. and K.G.H. analysed the data. G. A.T.C. contributed to the writing of the manuscript. H.S., J.W., C.B. and Z.M.R. provided vital new reagents and contributed to the writing of the manuscript. B.N. conceived the study, designed research, analysed data and wrote the manuscript.
